Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADAM17 | P78536 | 2/20 | 0.44 |
| ▸ | MEP1B | Q16820 | 2/20 | 0.41 |
| ▸ | BACE1 | P56817 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.38 |
| ▸ | HTT | P42858 | 1/20 | 0.38 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.38 |
| ▸ | ANPEP | P15144 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2876648 | 0.81 | MEP1B (0.48) | MEP1BBACE1ALDH1A1LMNAMAPK1 | |
| SCHEMBL404304 | 0.81 | ALDH1A1 (0.52) | ADAM17MEP1BALDH1A1LMNAMAPK1 | |
| SCHEMBL12064314 | 0.81 | ALDH1A1 (0.52) | ADAM17MEP1BALDH1A1LMNAMAPK1 | |
| SCHEMBL399676 | 0.81 | ALDH1A1 (0.52) | ADAM17MEP1BALDH1A1LMNAMAPK1 | |
| SCHEMBL399832 | 0.81 | ALDH1A1 (0.52) | ADAM17MEP1BALDH1A1LMNAMAPK1 | |
| SCHEMBL2258599 | 0.78 | MEP1B (0.54) | MEP1B | |
| SCHEMBL402286 | 0.77 | MEP1B (0.43) | ADAM17MEP1BALDH1A1LMNAMAPK1 | |
| SCHEMBL402593 | 0.77 | BACE1 (0.47) | MEP1BBACE1ALDH1A1LMNAMAPK1 | |
| SCHEMBL10286652 | 0.75 | SDCBP (0.49) | MEP1BNPSR1 | |
| SCHEMBL2256425 | 0.75 | ADAM17 (0.39) | ADAM17MEP1BALDH1A1LMNAMAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8153843-B2 | Antibacterial agents | UNIVERSITY OF WASHINGTON (US) | 2012-04-10 | — | — | US | disclosed |
| US-8101640-B2 | Antibacterial agents | NOVARTIS VACCINES AND DIAGNOSTICS, INC. (US) | 2012-01-24 | — | — | US | disclosed |
| US-20110172174-A1 | Antibacterial agents | NOVARTIS VACCINES AND DIAGNOSTICS INC. | 2011-07-14 | — | — | US | disclosed |
| US-7358359-B2 | Antibacterial agents | UNIVERSITY OF WASHINGTON (US) | 2008-04-15 | — | — | US | disclosed |
| US-20060154988-A1 | Antibacterial agents | UNIVERSITY OF WASHINGTON (US) | 2006-07-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110172174-A1 | Antibacterial agents | MRPL21, SI, PGLS | ADAM17 1862/4885MEP1B 1047/4885BACE1 1994/4885 |
| US-20060154988-A1 | Antibacterial agents | MRPL21, SI, PGLS | ADAM17 1862/4885MEP1B 1047/4885BACE1 1994/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.